Ferinzhekt, 50 mg/ml 10 ml

Pherinject is a preparation of iron. It is a carboxymaltosate complex of multinuclear iron(III) hydroxide.

After parenteral administration the macromolecular complex is taken up by the reticulo-endothelial system and breaks down into iron and carboxymaltose.

The iron enters the bloodstream, where it binds to the transport protein transferrin.

The iron in complex with transferrin is transported to body cells, where it is used for the synthesis of hemoglobin, myoglobin and a large number of enzymes or accumulated as ferritin.

Indications

Anemia

Iron deficiency anemia when oral iron preparations are ineffective or cannot be used.

The diagnosis must be confirmed by laboratory tests.

Active ingredient

Iron carboxymaltosate

Composition

1 ml. solution for intravenous injection contains:

the active ingredient:

iron carboxymaltosate 50 mg

How to take, the dosage

Perinject should be administered intravenously (by jet or drip) and by direct injection into the venous area of the dialysis system.

Bottles should be inspected for possible sediment and damage before opening.

Only a homogenous solution without residue may be used.

Drip administration: Ferinject may be administered intravenously by drip at a maximum single dose of up to 20 ml (1000 mg of iron), which should not exceed 0.3 ml (15 mg of iron)/kg body weight or the calculated cumulative dose.

Perinject drip infusion at a dose of 20 ml more than once a week should not be administered.

Contraindications

• anemias not related to iron deficiency;
• symptoms of iron overload or iron utilization disorders;
• .
• pregnancy I trimester;
• children under 14 years of age;
• high sensitivity to the components of Ferinject.

With caution, use the drug in patients with hepatic insufficiency, acute or chronic infectious diseases (suppression of erythropoiesis is possible), bronchial asthma, eczema, atopic allergy.

.

Side effects

Allergic reactions: common – rash; infrequent – urticaria, hypersensitivity reactions, including anaphylactoid reactions.

Nervous system disorders: often – headache; dizziness; infrequent – paresthesias.

Cardiovascular system: infrequent – decrease of blood pressure, “rushes” of blood to the face.

Respiratory system: rarely – shortness of breath.

The digestive system: frequently – nausea, abdominal pain, diarrhea, constipation; infrequently – change in taste, vomiting, dyspepsia, flatulence.

Muscular system: infrequent – myalgia, back pain, arthralgia.

General reactions: infrequent – fever, fatigue, chest pain, chills, malaise, peripheral edema.

Local reactions: often – reactions at the site of administration.

Laboratory parameters: often – increase of serum ALT, transient decrease of serum phosphate; infrequent – increase of ACT, GGT, LDH activity.

.

Overdose

Symptoms: Ferinecretin in amounts that exceed the body’s needs can cause iron overload, which manifests as symptoms of hemosiderosis. Determination of iron metabolism indicators such as serum ferritin and transferrin saturation percentage can help diagnose excessive iron deposition in the body.

Treatment: conducting symptomatic therapy. If necessary, chelated compounds (e.g., deferoxamine) may be used.

.